Lacosamide Shortage: What Providers and Prescribers Need to Know in 2026

Lacosamide Availability in 2026: A Provider Briefing

As a prescriber managing patients with epilepsy, you're likely aware that medication access challenges extend well beyond formal FDA shortage listings. Lacosamide (Vimpat) — a widely prescribed antiepileptic drug for focal and primary generalized tonic-clonic seizures — has been the subject of intermittent pharmacy-level availability concerns since generic entry in 2022.

This briefing provides an up-to-date picture of Lacosamide supply, prescribing considerations, cost dynamics, and tools you can use to help your patients maintain uninterrupted therapy.

Current Supply Status: Timeline and Context

Lacosamide is not listed on the FDA or ASHP drug shortage databases as of early 2026. However, clinicians and patients continue to report sporadic difficulty filling prescriptions at retail pharmacies. The pattern is consistent with a distribution-level disruption rather than a manufacturing-level shortage:

• 2008: Vimpat (brand) approved by FDA; UCB was sole manufacturer
• 2022: First generic Lacosamide products approved and launched
• 2022-2024: Transition period as generic manufacturers ramped production; occasional supply gaps at specific pharmacy chains
• 2025-2026: Market has stabilized with multiple generic suppliers, though individual manufacturer disruptions still cause localized stock-outs

The controlled substance classification (Schedule V) adds friction to the reorder process. Pharmacies face DEA reporting requirements and may maintain lower inventory levels for Schedule V drugs, increasing the likelihood that a routine demand spike triggers a temporary stock-out.

Prescribing Implications

When patients report difficulty filling Lacosamide, consider the following:

Avoid Abrupt Discontinuation

As with all AEDs, abrupt discontinuation of Lacosamide carries a risk of increased seizure frequency and status epilepticus. If a patient cannot access their medication, prioritize strategies to maintain continuity of therapy rather than waiting for stock to return.

Formulation Flexibility

Lacosamide is available in three formulations:

• Oral tablets: 50 mg, 100 mg, 150 mg, 200 mg
• Oral solution: 10 mg/mL
• IV injection: 10 mg/mL (200 mg/20 mL vials)

If a specific tablet strength is unavailable, consider prescribing an alternative strength combination (e.g., two 100 mg tablets instead of one 200 mg) or the oral solution. Pharmacies may have different formulations in stock even when a particular tablet strength is not available.

Generic Substitution Considerations

Multiple generic manufacturers now produce Lacosamide. While generics are rated as therapeutically equivalent (AB-rated), some patients — particularly those with well-controlled seizures — may report subjective differences when switching between manufacturers. If a patient experiences a change in seizure control or tolerability after a manufacturer switch, document the preferred manufacturer (NDC) to facilitate consistent dispensing.

The Availability Picture

Current availability data suggests:

• Generic Lacosamide tablets are generally available through major wholesalers (McKesson, AmerisourceBergen, Cardinal Health), though specific strengths and manufacturers may experience periodic allocation limits
• Brand-name Vimpat remains available through UCB's distribution channels, including a Direct-to-Patient Program
• Oral solution and IV formulations may have more limited availability at retail pharmacies due to lower demand and higher unit costs

Chain pharmacies (CVS, Walgreens, Rite Aid) use centralized ordering systems that can be slower to respond to allocation changes. Independent pharmacies often have access to secondary wholesalers and may serve as an alternative source for patients.

Cost and Access Considerations

Cost remains a barrier for many patients, even with insurance coverage:

• Brand Vimpat retail: ~$1,000-$1,100/month (60 tablets)
• Generic Lacosamide retail: ~$300-$500/month without discounts
• Generic with coupon: $24-$45/month (GoodRx, SingleCare)
• UCB Direct-to-Patient: $79.99-$84.99 for 60 tablets of brand Vimpat

Most commercial insurance plans and Medicare Part D cover generic Lacosamide with a preferred tier copay of $10-$50. Brand-name Vimpat may require prior authorization with demonstration of generic failure or intolerance.

Patient Assistance

For uninsured or underinsured patients, UCB Cares Patient Assistance Program provides free Vimpat to qualifying individuals. Eligibility is income-based. Patients can apply at ucb-usa.com or call 1-844-599-CARE.

Tools and Resources for Your Practice

Several tools can help you and your patients navigate availability challenges:

• Medfinder for Providers: Real-time pharmacy stock search to help patients locate Lacosamide near their location
• ASHP Drug Shortages Resource Center: Monitor for any formal shortage listings at ashp.org
• FDA Drug Shortage Database: accessdata.fda.gov for official shortage updates
• UCB Medical Information: For product-specific questions, contact UCB Medical Affairs

Consider building a workflow where clinical staff proactively check availability when writing or renewing Lacosamide prescriptions, especially for patients who have reported access difficulties in the past.

Alternative Agents

If a patient cannot access Lacosamide and requires a therapeutic switch, consider these alternatives based on seizure type and patient profile:

• Oxcarbazepine (Trileptal): Sodium channel blocker; well-established for focal seizures; affordable generic; monitor for hyponatremia
• Eslicarbazepine (Aptiom): Enhances slow inactivation of sodium channels (mechanism most similar to Lacosamide); once-daily dosing; limited generic availability; higher cost
• Carbamazepine (Tegretol): Classic sodium channel blocker; very affordable; significant drug interactions (CYP3A4 induction); HLA-B*1502 testing recommended in at-risk populations
• Levetiracetam (Keppra): Different mechanism (SV2A binding); broad-spectrum efficacy; minimal drug interactions; very affordable; psychiatric side effects (irritability) in some patients

For a patient-facing version of this information, refer patients to: Alternatives to Lacosamide.

Looking Ahead

The Lacosamide generic market is maturing. As additional manufacturers enter and supply chains stabilize, pharmacy-level stock-outs should become less frequent. However, the controlled substance classification and the inherently thin margins of generic manufacturing mean that intermittent disruptions are likely to persist.

Proactive communication with patients, familiarity with alternative sourcing strategies, and awareness of cost-assistance programs will remain essential components of epilepsy care management.

Final Thoughts

Lacosamide availability in 2026 is generally adequate but not without gaps. Patients who report difficulty filling prescriptions are not imagining the problem — localized stock-outs are real and ongoing. As a prescriber, you can make a meaningful difference by leveraging tools like Medfinder for Providers, staying flexible with formulations and strengths, and keeping alternative agents in your therapeutic toolkit.

For a patient-oriented overview, direct your patients to our Lacosamide shortage update for patients. For cost-saving strategies to share with patients, see our provider's guide to helping patients save money on Lacosamide.